Chronic Rhinosinusitis Trial, Recruiting NCT04645511 Sponsor: Tampere University Hospital Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Recruiting

NCT04645511
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are aged 18 to 69 years old
  • You are willing to take part in the study
  • You have been diagnosed with either chronic maxillary sinusitis (long-lasting sinus problems lasting 12 weeks or more) or recurring acute maxillary sinusitis (4 or more short sinus infections per year)
  • If you have chronic maxillary sinusitis, your symptoms have not improved after at least 3 months of using a steroid nasal spray
  • If you have chronic maxillary sinusitis, your symptom score on a standard questionnaire (called SNOT-22) is 8 points or higher
  • If you have recurring acute sinus infections, there is no minimum symptom score required
  • If you have chronic maxillary sinusitis, your CT scan results show that the inflammation is mainly limited to the upper cheek sinuses, with only minor or no involvement of other sinuses (confirm with trial site)

Who may not be able to join:

  • You have chronic sinusitis with nasal polyps (growths inside the nose)
  • You have significant inflammation in the sinuses behind or above your eyes, in addition to your cheek sinus problems
  • You have had previous nasal or sinus surgery
  • You have a tumour in your nose or sinuses
  • Your sinus problems are caused by a dental issue
  • Your facial pain is caused by something other than sinusitis
  • You have cystic fibrosis
  • You have a seriously weakened immune system
  • You have an inherited condition affecting the tiny hairs in your airways that help clear mucus (confirm with trial site)
  • You have a fungal infection in your sinuses
  • You have a condition involving inflammation of your blood vessels or certain types of tissue disease (confirm with trial site)
  • You have a serious ongoing illness affecting your overall health
  • You have or have had cancer
  • You are pregnant
  • You are currently experiencing an active sinus infection or a flare-up of your symptoms at the time of enrolment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Markus Rautiainen, Professor, Professor

Phone: +358407480866

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tampere University Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2021
Est. completion
31 December 2026

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Change from baseline Sino-Nasal Outcome Test (SNOT-22) score at 3 months; Change from baseline Sino-Nasal Outcome Test (SNOT-22) score at 6 months; Change from baseline Sino-Nasal Outcome Test (SNOT-22) score at 9 months; Change from baseline Sino-Nasal Outcome Test (SNOT-22) score at 12 months; Change from baseline in the number of acute rhinosinusitis infections at 3 months; Change from baseline in the number of acute rhinosinusitis infections at 6 months; Change from baseline in the number of acute rhinosinusitis infections at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov